AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

Alzheimer's Disease (AD), the leading cause of dementia, affects nearly 40 million individuals globally, resulting in a ...

Scripta's unique approach is based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of the ...

AbbVie and Calico first inked their partnership in 2014 with up to $1.5 billion in funding to advance therapies for diseases, ...

Boosting levels of a certain molecule that declines with age was found to restore memory and brain function in Alzheimer’s ...

A drug candidate found to protect nerve cells damaged by motor neuron disease (MND), could offer new hope to people living ...

When researchers sampled brain tissue of stranded dolphins, they found Alzheimer’s disease-like developments and drastically ...

HUPO says it selected the C2N and WashU Medicine teams because their "exceptional achievements have significantly advanced the field of proteomics. Each award recognizes excellence, innovation, and ...

Four University of Rhode Island researchers have developed and tested a cost-effective, easy-to-use tabletop device that can ...